{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:36:31Z","timestamp":1790753791881,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.anai.2018.03.017","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T03:31:57Z","timestamp":1521430317000},"page":"320-327","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Hepatitis B vaccine nonresponders"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0603-2797","authenticated-orcid":false,"given":"Tara Vinyette","family":"Saco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6313-7221","authenticated-orcid":false,"given":"Alexandra T.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-7075","authenticated-orcid":false,"given":"Dennis K.","family":"Ledford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2018.03.017_bib0010","author":"CDC"},{"key":"10.1016\/j.anai.2018.03.017_bib0015","author":"World Health Organization"},{"key":"10.1016\/j.anai.2018.03.017_bib0020","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.anai.2018.03.017_bib0025","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1440-1746.2010.06574.x","article-title":"Changing etiologies and outcomes of acute liver failure: A perspective from Japan","volume":"26","author":"Oketani","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2018.03.017_bib0030","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4254\/wjh.v7.i24.2503","article-title":"Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine","volume":"7","author":"Walayat","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.anai.2018.03.017_bib0035","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1093\/hmg\/ddt586","article-title":"A genome-wide association study identifies polymorphisms in the HLA-DR region associated with non-response to hepatitis B vaccination in Chinese Han populations","volume":"23","author":"Pan","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.anai.2018.03.017_bib0040","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/jmv.23934","article-title":"BTNL2 associated with the immune response to hepatitis B vaccination in a Chinese Han population","volume":"86","author":"Yang","year":"2014","journal-title":"J Med Virol"},{"key":"10.1016\/j.anai.2018.03.017_bib0045","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/gene.2013.62","article-title":"HLA-DPB1 and anti-HBs titer kinetics in hepatitis B booster recipients who completed primary hepatitis B vaccination during infancy","volume":"15","author":"Wu","year":"2014","journal-title":"Genes Immun"},{"key":"10.1016\/j.anai.2018.03.017_bib0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.vaccine.2016.08.068","article-title":"Identification of amino acids in antigen-binding site of class II HLA proteins independently associated with hepatitis B vaccine response","volume":"35","author":"Sakai","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.cld.2010.05.012","article-title":"Hepatitis B immunology for clinicians","volume":"14","author":"Chang","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.anai.2018.03.017_bib0060","first-page":"449","article-title":"Decline of HBsAg antibodies after immunization with hepatitis B vaccines and after natural infection","volume":"70","author":"Braito","year":"1991","journal-title":"Boll DellIstituto Sieroter Milan"},{"key":"10.1016\/j.anai.2018.03.017_bib0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2017.07.006","article-title":"Mechanisms of hepatitis B virus persistence","volume":"26","author":"Tsai","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.anai.2018.03.017_bib0070","article-title":"Hepatitis B vaccines: WHO position paper, July 2017 \u2013 Recommendations","author":"World Health Organization","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0075","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.vaccine.2012.12.077","article-title":"A novel hepatitis B vaccine containing AdvaxTM, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing","volume":"31","author":"Saade","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0080","doi-asserted-by":"crossref","first-page":"882","DOI":"10.2174\/1389201016666150505122422","article-title":"Nasal vaccines against hepatitis B: An update","volume":"16","author":"Almeida","year":"2015","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.anai.2018.03.017_bib0085","doi-asserted-by":"crossref","first-page":"654","DOI":"10.4161\/hv.7.6.14986","article-title":"Hepatitis B vaccination strategy in vaccine low and non-responders: A matter of quantity of quality?","volume":"7","author":"Roukens","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.anai.2018.03.017_bib0090","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1038\/ijo.2013.16","article-title":"Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection","volume":"37","author":"O'Shea","year":"2013","journal-title":"Int J Obes"},{"key":"10.1016\/j.anai.2018.03.017_bib0095","doi-asserted-by":"crossref","DOI":"10.5402\/2011\/980105","article-title":"Altered or impaired immune response to hepatitis B vaccine in WNIN\/GR-Ob rat: an obese rat model with impaired glucose tolerance","volume":"2011","author":"Bandaru","year":"2011","journal-title":"ISRN Endocrinol"},{"key":"10.1016\/j.anai.2018.03.017_bib0100","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.4161\/hv.24480","article-title":"Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen","volume":"9","author":"Rosenberg","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.anai.2018.03.017_bib0105","doi-asserted-by":"crossref","first-page":"10383","DOI":"10.3748\/wjg.v20.i30.10383","article-title":"Hepatitis B vaccine by intradermal route in non responder patients: An update","volume":"20","author":"Filippelli","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0110","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.vaccine.2008.04.038","article-title":"HLA and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination","volume":"26","author":"Lin","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0115","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00439-013-1320-5","article-title":"Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents","volume":"132","author":"Wu","year":"2013","journal-title":"Hum Genet"},{"key":"10.1016\/j.anai.2018.03.017_bib0120","first-page":"157","article-title":"Non-responsiveness to hepatitis B vaccination in HIV seropositive patients: possible causes and solutions","volume":"11","author":"van den Berg","year":"2009","journal-title":"AIDS Rev"},{"key":"10.1016\/j.anai.2018.03.017_bib0125","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1016\/j.vaccine.2014.04.049","article-title":"Delayed-type hypersensitivity and hepatitis B vaccine responses, in vivo markers of cellular and humoral immune function, and the risk of AIDS or death","volume":"32","author":"Patterson","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0130","doi-asserted-by":"crossref","first-page":"649","DOI":"10.4049\/jimmunol.1302069","article-title":"KLRG1 impairs CD4+ T cell responses via p16ink4a and p27kip1 pathways: role in hepatitis B vaccine failure in individuals with hepatitis C virus infection","volume":"192","author":"Shi","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.anai.2018.03.017_bib0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/hepr.13008","article-title":"Immune response to hepatitis B vaccine in patients with chronic hepatitis C infection: a systematic review and meta-analysis","volume":"48","author":"Liu","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.anai.2018.03.017_bib0140","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2011.02.052","article-title":"Impaired hepatitis B vaccine responses during chronic hepatitis C infection: involvement of the PD-1 pathway in regulating CD4(+) T cell responses","volume":"29","author":"Moorman","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0145","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.vaccine.2013.03.003","article-title":"Tim-3 alters the balance of IL-12\/IL-23 and drives TH17 cells: role in hepatitis B vaccine failure during hepatitis C infection","volume":"31","author":"Wang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0150","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1365-2567.2009.03106.x","article-title":"Abnormal B-cell activation associated with TALL-1 over-expression and SOCS-1 suppression during chronic hepatitis C virus infection","volume":"128","author":"Moorman","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.anai.2018.03.017_bib0155","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.3748\/wjg.v20.i34.12018","article-title":"Factors affecting effectiveness of vaccination against hepatitis B virus in hemodialysis patients","volume":"20","author":"Eleftheriadis","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0160","doi-asserted-by":"crossref","first-page":"315","DOI":"10.14740\/jocmr1999w","article-title":"Variability in response to hepatitis B vaccine in hemodialysis patients","volume":"7","author":"El-Charabaty","year":"2015","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.anai.2018.03.017_bib0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1525-139X.2007.00283.x","article-title":"Disturbances of acquired immunity in hemodialysis patients","volume":"20","author":"Eleftheriadis","year":"2007","journal-title":"Semin Dial"},{"key":"10.1016\/j.anai.2018.03.017_bib0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4254\/wjh.v7.i5.761","article-title":"Is hemodialysis a reason for unresponsiveness to hepatitis B vaccine? Hepatitis B virus and dialysis therapy","volume":"7","author":"Sit","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.anai.2018.03.017_bib0175","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10238-007-0127-x","article-title":"Decreased antigen-specific T-cell proliferation by moDC among hepatitis B vaccine non-responders on haemodialysis","volume":"7","author":"Verkade","year":"2007","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.anai.2018.03.017_bib0180","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s11255-011-0043-6","article-title":"Good response to HBsAg vaccine in dialysis patients is associated with high CD4+\/CD8+ ratio","volume":"44","author":"Sari","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.anai.2018.03.017_bib0185","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1046\/j.1523-1755.2001.00062.x","article-title":"The interleukin-10 promoter genotype determines clinical immune function in hemodialysis patients","volume":"60","author":"Girndt","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.anai.2018.03.017_bib0190","first-page":"1046","article-title":"CD4(+) CD25(+) FoxP3(+) T regulatory cells in subjects responsive or unresponsive to hepatitis B vaccination","volume":"36","author":"Li","year":"2011","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.anai.2018.03.017_bib0195","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/j.vaccine.2012.01.064","article-title":"Hepatitis B virus vaccine in chronic kidney disease: Improved immunogenicity by adjuvants? A meta-analysis of randomized trials","volume":"30","author":"Fabrizi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0200","first-page":"1","article-title":"Hepatitis B vaccine nonresponse: an alarm signal for latent type 1 diabetes?","volume":"4","author":"Mormile","year":"2013","journal-title":"J Diabetes Metab"},{"key":"10.1016\/j.anai.2018.03.017_bib0205","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.3748\/wjg.v23.i18.3205","article-title":"Immune response to vaccines in children with celiac disease","volume":"23","author":"Anania","year":"2017","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0210","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4318\/tjg.2011.0152","article-title":"Responsiveness of children with celiac disease to different hepatitis B vaccination protocols","volume":"22","author":"Balamtek\u0131n","year":"2011","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0215","doi-asserted-by":"crossref","first-page":"e30888","DOI":"10.5812\/hepatmon.30888","article-title":"Extending the debate on poor response to hepatitis B virus vaccination in children with celiac disease: which question remains?","volume":"15","author":"Leonardi","year":"2015","journal-title":"Hepat Mon"},{"key":"10.1016\/j.anai.2018.03.017_bib0220","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3748\/wjg.v19.i6.838","article-title":"Hepatitis B vaccine in celiac disease: yesterday, today and tomorrow","volume":"19","author":"Vitaliti","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/jgh.12712","article-title":"Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination","volume":"30","author":"Cossio-Gil","year":"2015","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.anai.2018.03.017_bib0230","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.vaccine.2017.03.080","article-title":"Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"35","author":"Jiang","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0235","doi-asserted-by":"crossref","first-page":"11273","DOI":"10.3748\/wjg.v21.i40.11273","article-title":"Immunogenicity and mechanisms impairing the response to vaccines in inflammatory bowel disease","volume":"21","author":"Mar\u00edn","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0240","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.vaccine.2013.04.059","article-title":"Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease","volume":"31","author":"Sempere","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0245","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1038\/ajg.2012.79","article-title":"Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease","volume":"107","author":"Gisbert","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0250","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/cmi.2015.01","article-title":"Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model","volume":"12","author":"Chyuan","year":"2015","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.anai.2018.03.017_bib0255","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s10157-011-0464-7","article-title":"Prevention of hepatitis B virus reactivation in immunosuppressive therapy or chemotherapy","volume":"15","author":"Ohishi","year":"2011","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.anai.2018.03.017_bib0260","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1016\/j.vaccine.2014.02.094","article-title":"Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults","volume":"32","author":"Pan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0265","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.vaccine.2007.10.044","article-title":"Low dose revaccination induces robust protective anti-HBs antibody response in the majority of healthy non-responder neonates","volume":"26","author":"Jafarzadeh","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0270","doi-asserted-by":"crossref","DOI":"10.1177\/2050312114563346","article-title":"Evaluation of the response to vaccination with hepatitis B vaccine in pediatric patients diagnosed with celiac disease","volume":"2","author":"Walkiewicz-Jedrzejczak","year":"2014","journal-title":"SAGE Open Med"},{"key":"10.1016\/j.anai.2018.03.017_bib0275","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13312-017-1203-2","article-title":"Double dose versus standard dose hepatitis B vaccine in HIV-infected children: a randomized controlled trial","volume":"54","author":"Siddiqui","year":"2017","journal-title":"Indian Pediatr"},{"key":"10.1016\/j.anai.2018.03.017_bib0280","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14760584.2017.1367667","article-title":"Immunogenicity, antibody persistence, and safety of the 60\u2009\u00b5g hepatitis B vaccine in hemodialysis patients: a multicenter, randomized, double-blind, parallel-controlled trial","volume":"16","author":"Feng","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.anai.2018.03.017_bib0285","doi-asserted-by":"crossref","first-page":"e8575","DOI":"10.1097\/MD.0000000000008575","article-title":"Seroconverting nonresponder of high-dose intramuscular HBV vaccine with intradermal HBV vaccine","volume":"96","author":"Das","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.anai.2018.03.017_bib0290","doi-asserted-by":"crossref","first-page":"4892","DOI":"10.1016\/j.vaccine.2015.07.051","article-title":"Advax delta inulin adjuvant overcomes immune immaturity in neonatal mice thereby allowing single-dose influenza vaccine protection","volume":"33","author":"Honda-Okubo","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0295","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1016\/j.vaccine.2015.09.030","article-title":"Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety","volume":"33","author":"Petrovsky","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0300","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.4161\/hv.24256","article-title":"Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine","volume":"9","author":"Halperin","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.anai.2018.03.017_bib0305","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0310","first-page":"143","article-title":"Immunogenicity of Sci-B-Vac (a third-generation hepatitis B vaccine) in HIV-positive adults","volume":"19","author":"Alon","year":"2017","journal-title":"Isr Med Assoc J IMAJ"},{"key":"10.1016\/j.anai.2018.03.017_bib0315","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.3748\/wjg.v21.i24.7400","article-title":"Applications of human hepatitis B virus preS domain in bio- and nanotechnology","volume":"21","author":"Toita","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.anai.2018.03.017_bib0320","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/vaccines2010160","article-title":"DNA\/MVA vaccines for HIV\/AIDS","volume":"2","author":"Iyer","year":"2014","journal-title":"Vaccines."},{"key":"10.1016\/j.anai.2018.03.017_bib0325","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/j.1365-2036.2006.03035.x","article-title":"Meta-analysis: the adjuvant role of granulocyte macrophage-colony stimulating factor on immunological response to hepatitis B virus vaccine in end-stage renal disease","volume":"24","author":"Fabrizi","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.anai.2018.03.017_bib0330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clinthera.2010.01.005","article-title":"Effects of oral levamisole as an adjuvant to hepatitis B vaccine in adults with end-stage renal disease: a meta-analysis of controlled clinical trials","volume":"32","author":"Alavian","year":"2010","journal-title":"Clin Ther"},{"key":"10.1016\/j.anai.2018.03.017_bib0335","doi-asserted-by":"crossref","first-page":"4938","DOI":"10.1016\/j.vaccine.2009.06.012","article-title":"Levamisole is a potential facilitator for the activation of Th1 responses of the subunit HBV vaccination","volume":"27","author":"Zhang","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0340","first-page":"219","article-title":"The effect of oral levamisole co-administration on the level of immune response to hepatitis B vaccine in healthy individuals: a randomized clinical trial","volume":"16","author":"Hosseini","year":"2017","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"10.1016\/j.anai.2018.03.017_bib0345","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/sji.12018","article-title":"Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice","volume":"77","author":"Niu","year":"2013","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.anai.2018.03.017_bib0350","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40262-015-0243-9","article-title":"A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole","volume":"54","author":"Pawluk","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.anai.2018.03.017_bib0355","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.vaccine.2009.10.101","article-title":"Enhancement of humoral and cellular responses to HBsAg DNA vaccination by immunization with praziquantel through inhibition TGF-beta\/Smad2,3 signaling","volume":"28","author":"Zou","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.anai.2018.03.017_bib0360","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.4161\/hv.28517","article-title":"Cimetidine synergizes with Praziquantel to enhance the immune response of HBV DNA vaccine via activating cytotoxic CD8(+) T cell","volume":"10","author":"Xie","year":"2014","journal-title":"Hum Vaccines Immunother"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618302151?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120618302151?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:19:42Z","timestamp":1761052782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120618302151"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":71,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1081120618302151"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2018.03.017","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B vaccine nonresponders","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2018.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}